OneSource Specialty Pharma Limited has notified the stock exchanges of an upcoming Board of Directors meeting scheduled for Wednesday, May 13, 2026. The intimation was filed on May 07, 2026, in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Board Meeting Details

The board meeting has been convened to consider and approve the audited financial results of the company for the quarter and year ended March 31, 2026. The results will be reviewed on both a standalone and consolidated basis, along with other matters as may be taken up during the meeting.

Key details of the scheduled board meeting are summarised below:

Trading Window Closure

In line with the provisions of the Company's Code of Conduct under the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for Designated Persons of the company has been closed effective April 01, 2026, for the quarter ended March 31, 2026. The trading window will reopen 48 hours after the dissemination of the financial results by the company.

The intimation was submitted by Trisha A, Company Secretary and Compliance Officer (Membership Number: A47635), on behalf of OneSource Specialty Pharma Limited.

OneSource Specialty Pharma announced that its partner Orbicular, along with its Canadian front-end partner, has received approval from Health Canada for a generic version of Ozempic® (semaglutide injection). This marks the second generic semaglutide approval in Canada, positioning OneSource partners as the first generic entrants in what is recognized as the world's second-largest semaglutide market.

Strategic Market Milestone

The latest regulatory approval represents a significant achievement for OneSource's expanding portfolio of complex pharmaceutical partnerships in one of the world's most important semaglutide markets. The milestone reflects a closely integrated development and manufacturing model where Orbicular led the product development and technical program for the complex peptide, while OneSource supported the program as the manufacturing partner.

Manufacturing and Supply Chain Excellence

OneSource provided end-to-end manufacturing capabilities for the Canadian filing, with commercial supply to be supported from the company's US FDA-approved flagship facility in Bengaluru. The approval follows a recent tentative approval in the United States supported by OneSource, further reinforcing the company's growing presence in complex peptide-based injectable programs across highly regulated markets.

Global Market Expansion

The Canadian approval builds on momentum from India, where OneSource has been supplying multiple brands marketed by various partners following product launches in March. This strategic positioning establishes the company as a key player in the global semaglutide market across multiple jurisdictions, with particular strength in enabling first-to-market generic entries.

Mr. Neeraj Sharma, CEO & MD of OneSource Specialty Pharma Limited, commented: "We are pleased with these back-to-back approvals from two of our global customers in one of the most important semaglutide markets globally. This milestone reflects the strength of our CDMO platform, our compliance standards, technical expertise, and ability to scale complex drug-device-combination programs for highly regulated markets. Our partnership with Orbicular highlights our role in enabling global commercialization through strong, collaborative ecosystems."

CDMO Platform Capabilities

With a continued focus on complex drug-device combinations, biologics, and oral technology, OneSource is strengthening its position as a global CDMO partner. The company enables faster, reliable, and high-quality commercialization for partners worldwide through its comprehensive manufacturing and development capabilities across five state-of-the-art facilities.